EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia

BACKGROUND: Cerebral vasculopathy in sickle cell anemia (SCA) begins in childhood and features intracranial arterial stenosis with high risk of ischemic stroke. Stroke risk can be reduced by transcranial doppler (TCD) screening and chronic transfusion therapy; however, this approach is impractical i...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JMIR Res Protoc
Auteurs principaux: Rankine-Mullings, Angela E, Little, Courtney R, Reid, Marvin E, Soares, Deanne P, Taylor-Bryan, Carolyn, Knight-Madden, Jennifer M, Stuber, Susan E, Badaloo, Asha V, Aldred, Karen, Wisdom-Phipps, Margaret E, Latham, Teresa, Ware, Russell E
Format: Artigo
Langue:Inglês
Publié: JMIR Publications 2016
Sujets:
Original Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5037317/
https://ncbi.nlm.nih.gov/pubmed/27619954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2196/resprot.5872
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires